Core Viewpoint - Kanghong Pharmaceutical has received the drug registration certificate for Ipatasertib tablets from the National Medical Products Administration, indicating approval for the treatment of diabetic neuropathy [1] Company Summary - Kanghong Pharmaceutical (002773.SZ) has recently announced the approval of Ipatasertib tablets, which are specifically indicated for diabetic neuropathy [1]

Group 1 - The core point of the article is that Kanghong Pharmaceutical has received the drug registration certificate for Ipatasertib from the National Medical Products Administration, indicating regulatory approval for the drug [1] - The approved indication for Ipatasertib is diabetic neuropathy, which highlights the company's focus on addressing complications related to diabetes [1]

Core Viewpoint - Kanghong Pharmaceutical has received the drug registration certificate for Ipatasertib from the National Medical Products Administration, indicating a significant advancement in its product pipeline for treating diabetic neuropathy [1] Company Summary - Kanghong Pharmaceutical announced the receipt of the drug registration certificate for Ipatasertib, which is intended for the treatment of diabetic neuropathy [1]

Core Viewpoint - Kanghong Pharmaceutical has received the drug registration certificate for Ipatasertib tablets, indicating a significant regulatory approval for a new treatment for diabetic neuropathy [1][2]. Group 1: Drug Information - Drug Name: Ipatasertib Tablets [1] - Dosage Form: Tablet [1] - Specification: 50mg [1] - Indication: Diabetic neuropathy [1] Group 2: Regulatory Approval - Registration Classification: Chemical Drug Class 3 [2] - Approval Number: National Drug Approval Code H20255572 [2] - Approval Conclusion: The drug meets the requirements for registration as per the Drug Administration Law of the People's Republic of China [2]. Group 3: Mechanism and Clinical Research - Ipatasertib is a reversible non-competitive inhibitor of aldose reductase, selectively inhibiting the enzyme [2]. - Clinical studies have shown that Ipatasertib can inhibit the accumulation of sorbitol in red blood cells of patients with diabetic peripheral neuropathy, improving subjective symptoms and neurological dysfunction compared to the control group [2].

关于公司收到药品注册证书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整， 没有虚假记载、误导性陈述或重大遗漏。 证券代码：002773 证券简称：康弘药业 公告编号：2025-052 成都康弘药业集团股份有限公司 1 / 2 二、产品简介 成都康弘药业集团股份有限公司（以下简称"公司"）于近日收 到国家药品监督管理局签发的依帕司他片的《药品注册证书》（证书 编号：2025S02992），批准注册。现将相关情况公告如下： 一、药品基本信息 药品名称：依帕司他片 剂型：片剂 规格：50mg 适应症：糖尿病性神经病变。 注册分类：化学药品 3 类 批准文号：国药准字 H20255572 审批结论：根据《中华人民共和国药品管理法》及有关规定，经 审查，本品符合药品注册的有关要求，批准注册，发 给药品注册证书。 依帕司他是一种可逆性的醛糖还原酶非竞争性抑制剂，对醛糖还 原酶具有选择性抑制作用。临床研究显示，依帕司他能抑制糖尿病性 外周神经病变患者红细胞中山梨醇的积累，与对照组比较能改善患者 的自觉症状和神经功能障碍。 三、对公司的影响 本次依帕司他片获批上市，丰富了公司的产品管线。 由于医药产品的生产 ...

Core Insights - Kanghong Pharmaceutical (002773) reported that as of September 19, 2025, the number of shareholders is 24,909 [1] Company Summary - The company has engaged with investors through an interactive platform, providing updates on shareholder statistics [1]

Market Overview - The biopharmaceutical sector experienced a decline of 0.21% on September 25, with Nossland leading the drop [1] - The Shanghai Composite Index closed at 3853.3, down 0.01%, while the Shenzhen Component Index closed at 13445.9, up 0.67% [1] Stock Performance - Notable gainers in the biopharmaceutical sector included: - Aopu Mai (688293) with a closing price of 62.85, up 7.42% and a trading volume of 30,600 [1] - Rongchang Biotech (688331) closed at 108.50, up 3.43% with a trading volume of 89,200 [1] - Baipusais (301080) closed at 62.16, up 3.43% with a trading volume of 43,500 [1] - Major decliners included: - Nossland (430047) closed at 22.99, down 3.69% with a trading volume of 57,000 [2] - Wufan Biotech (301393) closed at 53.12, down 3.42% with a trading volume of 24,600 [2] - Kexing Pharmaceutical (688136) closed at 38.75, down 3.34% with a trading volume of 53,500 [2] Capital Flow - The biopharmaceutical sector saw a net outflow of 207 million yuan from institutional investors, while retail investors contributed a net inflow of 45.07 million yuan [2] - Notable capital flows included: - Rongchang Biotech (688331) with a net inflow of 1.021 billion yuan from institutional investors [3] - Junshi Biosciences (688180) with a net inflow of 35.36 million yuan from institutional investors [3] - Aopu Mai (688293) with a net inflow of 9.41 million yuan from institutional investors [3]

Core Viewpoint - Kanghong Pharmaceutical's stock has shown significant volatility, with a year-to-date increase of 96.63% but a recent decline in the last five and twenty trading days [1][2]. Group 1: Stock Performance - As of September 24, Kanghong Pharmaceutical's stock price was 37.36 CNY per share, with a market capitalization of 34.42 billion CNY [1]. - The stock experienced a net inflow of 5.30 million CNY from main funds, with large orders accounting for 13.33% of purchases [1]. - The stock has seen a 5.70% decline over the last five trading days and an 8.27% decline over the last twenty trading days [1]. Group 2: Financial Performance - For the first half of 2025, Kanghong Pharmaceutical reported a revenue of 2.45 billion CNY, representing a year-on-year growth of 6.95%, and a net profit of 730 million CNY, up 5.41% year-on-year [2]. - The company has distributed a total of 2.04 billion CNY in dividends since its A-share listing, with 1.04 billion CNY distributed in the last three years [3]. Group 3: Shareholder Information - As of September 10, the number of shareholders for Kanghong Pharmaceutical was 24,700, a decrease of 1.19% from the previous period [2]. - The average number of circulating shares per shareholder increased by 1.21% to 27,778 shares [2]. - The top ten circulating shareholders include Hong Kong Central Clearing Limited and several mutual funds, with notable changes in their holdings [3].

Core Viewpoint - 康弘药业 has made significant progress during the "14th Five-Year Plan" period, focusing on core technologies and expanding its product matrix in ophthalmology, psychiatry/neuroscience, and oncology, leading to a steady increase in performance and high-quality development [1] Financial Performance - The company's operating revenue increased from 3.605 billion yuan in 2021 to 4.453 billion yuan in 2024, while the non-net profit rose from 301 million yuan to 1.184 billion yuan during the same period [1] - In the first half of 2025, the operating revenue was 2.453 billion yuan, a year-on-year increase of 6.95%, and the non-net profit was 723 million yuan, up 6.51% [1] Development Philosophy - The company adheres to a development philosophy centered on market orientation, innovation, quality, and talent, aiming to create innovative products and services that benefit the public [2] Risk Management and Innovation - 康弘药业 balances innovation and risk management by conducting thorough research and making accurate judgments, focusing on policy risk assessment, market demand validation, and a well-structured R&D pipeline [3] Product Strategy - 康弘药业 aims to develop long-lifecycle blockbuster products, with 康柏西普 being a prime example, generating 1.345 billion yuan in revenue in the first half of 2025, accounting for 54.83% of total revenue [3] - The company has launched 利非司特滴眼液, the first of its kind in China, targeting the large dry eye patient population [4] Market Potential - The dry eye medication market in China is projected to reach 4.79 billion yuan in 2024, with a compound annual growth rate of 16% from 2020 to 2024, providing 康弘药业 with significant growth opportunities [5] Technological Advancements - 康弘药业 is investing in cutting-edge technologies such as gene therapy, antibody-drug conjugates, and synthetic biology, with ongoing clinical trials for various innovative products [6][7]

Core Viewpoint - 康弘药业 has made significant progress during the "14th Five-Year Plan" period, focusing on core technologies in ophthalmology, psychiatry/neuroscience, and oncology, leading to a robust product matrix and steady revenue growth [1][2] Financial Performance - The company's revenue increased from 3.605 billion yuan in 2021 to 4.453 billion yuan in 2024, while the net profit attributable to shareholders rose from 301 million yuan to 1.184 billion yuan during the same period [1] - In the first half of 2025, 康弘药业 reported a revenue of 2.453 billion yuan, a year-on-year increase of 6.95%, and a net profit of 723 million yuan, up 6.51% [1] Development Philosophy - The company adheres to a development philosophy centered on market orientation, innovation, quality, and talent, aiming to create innovative products and services that benefit the public [2] - 康弘药业 emphasizes a balance between innovation and risk management, focusing on deep research and accurate judgment to ensure sustainable development [2] Product Strategy - 康弘药业's flagship product, 康柏西普, has generated 1.345 billion yuan in revenue in the first half of 2025, accounting for 54.83% of total revenue, showcasing the company's strategy of building a competitive edge through cost-effectiveness and treatment convenience [2] - The company is actively seeking to develop more "super products" to mitigate risks associated with over-reliance on a single product [2] Market Opportunities - 康弘药业's newly approved 利非司特滴眼液 addresses a significant market need for dry eye treatment, with the dry eye medication market in China projected to reach 4.79 billion yuan by 2024, growing at a compound annual growth rate of 16% from 2020 to 2024 [3] - The company is investing in cutting-edge technologies such as gene therapy and synthetic biology, with ongoing clinical trials for its gene therapy products and a focus on expanding its market presence [4] Technological Advancements - 康弘药业 is advancing in gene therapy, with its product KH631 entering clinical phase II in China and KH658 progressing in both Chinese and U.S. clinical trials [4] - The company has also made strides in synthetic biology, with KH617 being the first domestically developed I-type new drug from synthetic biology to enter clinical trials, and it has received orphan drug designation from the FDA [4]